Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

Revenues from Contracts and Significant Customers (Tables)

3 Months Ended

Mar. 31, 2018

The Company has three marketed products, Targadox®, Luxamend® and Ceracade. Substantially all of the Company’s product revenues are recorded in the U.S. Substantially all of the Company’s collaboration revenues are from its collaboration with TGTX. Revenues by product and collaborator are summarized as follows (in thousands):

	Three months ended March 31, 2018
Targadox®	$	5,498
Other branded revenue		11
Total product revenues	$	5,509
TGTX		394
Total Revenue	$	5,903

Revenue From Contracts With Customers [Member]

Disaggregation of Revenue

The following presents National’s revenues from contracts with customers disaggregated by major business activity for the three months ended December 31, 2017 ($ in thousands):

($ in thousands)	For the Three Months Ended December 31, 2017
Revenues from customer contracts:
Commissions	$	25,618
Investment banking:
Underwriting		2,700
Private Placement		9,815
Advisory		1,314
Other		160
Sub-total National Revenue from contracts with customers		39,607
Other National revenue		9,915
Total National Revenue	$	49,522